| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth |
| 25 Sep 2026 |
Form 4: Morrell Martha, CHIEF MEDICAL OFFICER
Gave up 335 shares to cover exercise price or tax ($4.68K) |
| 21 Sep 2026 |
Form 4: Williams Patrick F., Chief Financial Officer
Gave up 1,162 shares to cover exercise price or tax ($16.6K) |
| 04 Sep 2026 |
Form 4: Becker Joel, Director
Gave up 1,310 shares to cover exercise price or tax ($19.3K) |
| 04 Sep 2026 | SCHEDULE 13G/A |
| 28 Aug 2026 |
Form 4: Becker Joel, Director
Gave up 1,126 shares to cover exercise price or tax ($15.9K) |
| 28 Aug 2026 |
Form 4: Morrell Martha, CHIEF MEDICAL OFFICER
Gave up 358 shares to cover exercise price or tax ($5.06K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth |
| 28 Jul 2026 |
8-K: Regulation FD Disclosure
— Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form and that additional clinical evidence from the NAUTILUS trial and literature supportin... |
| 25 Jun 2026 |
Form 4: Morrell Martha, CHIEF MEDICAL OFFICER
Gave up 335 shares to cover exercise price or tax ($5.43K) |
| 22 Jun 2026 |
Form 4: Geiger Uri, Director
Received 789 shares as a grant or award ($12.3K) |
| 22 Jun 2026 |
Form 4: Fischer Frank M, Director
Received 1,467 shares as a grant or award ($22.9K) |
| 22 Jun 2026 |
Form 4: Kumar Rakhi, Director
Received 989 shares as a grant or award ($15.5K) |
| 08 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 5, 2026, NeuroPace, Inc. held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually via live webcast. The following proposals were voted upon, and the final voting results with respect to each such proposal are... |
| 05 Jun 2026 |
Form 4: Huennekens R Scott, Director
Received 2,890 shares as a grant or award · Granted 5,368 Stock Option (Right to Buy) |
| 05 Jun 2026 |
Form 4: Fischer Frank M, Director
Received 2,890 shares as a grant or award · Granted 5,368 Stock Option (Right to Buy) |
| 05 Jun 2026 |
Form 4: Geiger Uri, Director
Received 2,890 shares as a grant or award · Granted 5,368 Stock Option (Right to Buy) |
Loading...